Julie Roberson
Family · Norman, OKNPI 1487056065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 684 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 27.7% of the total. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 684 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Bristol Myers Squibb$617
- Ironwood Pharmaceuticals, Inc$493
- Johnson & Johnson$463
- plus $2K from 18 others
What the payments were for
- Food & beverage$9,910100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 175 | $2,762 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 133 | $1,757 |
| Takeda Pharmaceuticals U.S.A., Inc. | 118 | $1,500 |
| Bristol Myers Squibb | 48 | $617 |
| Ironwood Pharmaceuticals, Inc | 50 | $493 |
| Johnson & Johnson | 29 | $463 |
| Pfizer | 21 | $358 |
| QOL Medical, LLC | 13 | $244 |
| Ardelyx, Inc. | 13 | $218 |
| Gilead | 14 | $207 |
| Aimmune Therapeutics, Inc. | 11 | $207 |
| Sanofi | 13 | $196 |
| Regeneron Healthcare Solutions, Inc. | 10 | $190 |
| Madrigal Pharmaceuticals | 5 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Phathom Pharmaceuticals, Inc. | 7 | $117 |
| Merck | 6 | $96 |
| Ipsen Biopharmaceuticals, Inc | 5 | $86 |
| Nestle Healthcare Nutrition Inc. | 4 | $71 |
| Lilly USA, LLC | 2 | $39 |
| Redhill Biopharma Inc. | 2 | $28 |
| Braintree Laboratories, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$121
How this compares
$9,957 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 31 | $220,181 |
| XifaxanRifaximin | 27 | $88,754 |
| ZenpepLipase/Protease/Amylase | 25 | $55,724 |
| RelistorMethylnaltrexone Bromide | 13 | $42,708 |
| CreonLipase/Protease/Amylase | 18 | $38,074 |
| LinzessLinaclotide | 39 | $25,339 |
| TrulancePlecanatide | 16 | $15,503 |
| Mesalamine | 36 | $15,227 |
| MotegrityPrucalopride Succinate | 15 | $10,866 |
| Dexlansoprazole DrDexlansoprazole | 24 | $9,544 |
| Omeprazole | 464 | $8,894 |
| Pantoprazole Sodium | 451 | $8,370 |
| Colestipol Hcl | 93 | $7,473 |
| Lubiprostone | 22 | $6,801 |
| Famotidine | 335 | $6,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $1,757 | $146,96556 claims |
| AbbVieCreon, Linzess | $2,762 | $63,41357 claims |
| Aimmune Therapeutics, Inc.Zenpep | $207 | $55,72425 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,500 | $10,86615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Norman
- Katherine BuckNorman$14K
- Jackson LaizureNorman$13K
- Jordan HarrisNorman$12K
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
- Shelby WrightStillwater$17K
- Amanda OblanderYukon$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.